Home / Business and Economy / China Bans Pharma Bribes, Reps Shift to Academia
China Bans Pharma Bribes, Reps Shift to Academia
12 May
Summary
- Pharma reps in China will focus on academic exchange, not sales.
- New regulation effective August 1, 2026, targets illicit practices.
- Companies and institutions face penalties for non-compliance.
Chinese authorities have issued a new regulation targeting the management of pharmaceutical representatives, with enforcement beginning August 1, 2026. The National Medical Products Administration and other government bodies announced that pharmaceutical representatives will now be responsible for academic promotion of drugs rather than sales activities. This significant shift aims to eliminate illicit practices such as bribery and unauthorized drug sales that disrupt fair market competition.
The regulation strictly prohibits representatives from engaging in sales-related tasks like collecting payments or handling invoices. Furthermore, they are barred from offering financial incentives tied to sales volumes or providing kickbacks to medical personnel and their families. Companies found employing representatives involved in commercial bribery will be forbidden from doing so. Medical institutions must also avoid unregistered representatives and accepting benefits from them.
This regulatory overhaul signifies a move from sales-driven influence to value creation through authentic, standardized medical information services. Experts believe this will ultimately benefit the profession and establish a more credible academic promotion system for innovative pharmaceutical companies.
